IMM-101

Phase 3Biologic

IImmodulon Therapeutics Ltd

IMM-101 is one of 122 biologic programs targeting Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

121

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

MelanomaActive, not recruiting

Pancreatic CancerActive, not recruiting

COVID-19Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

IMM-101

IImmodulon Therapeutics Ltd

Phase 3

1 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

Nexavar

Bayer

Preclinical

1 4

Singulair

AstraZeneca

Preclinical

1 5

Benadryl

PParkedale

Preclinical

1 6

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 7

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 8

Standard Preparation

LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Preclinical

1 9

Tpa

UUniversity of Florida

Preclinical

1 10

Moderna COVID-19 Vaccine

Moderna

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Colorectal Cancer

NCT05118724

Clinical

Trials by Indication[1]

Pancreatic Cancer2 trials

Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer

No longer available·IImpatients N.V. trading as myTomorrows··NCT04137822

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Completed·IImmodulon Therapeutics Ltd·Phase 2·NCT01303172·110 enrolled

Colorectal Cancer1 trial

Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin

Active, not recruiting·AAIO-Studien-gGmbH·Phase 2·NCT05118724·80 enrolled

Unresectable Cancer1 trial

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

Terminated·IImmodulon Therapeutics Ltd·Phase 1/2·NCT03009058·2 enrolled

COVID-191 trial

Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

Completed·CCanadian Cancer Trials Group·Phase 3·NCT04442048·195 enrolled

Melanoma1 trial

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

Completed·IImmodulon Therapeutics Ltd·Phase 2·NCT03711188·16 enrolled

1 more indication

ART1 trial

A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001

Terminated·IImmodulon Therapeutics Ltd·Phase 1/2·NCT01559818·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for IMM-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IMM-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IMM-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Immodulon Therapeutics Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: IImmodulon Therapeutics Ltd

IMM-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Pancreatic Cancer2 trials

Colorectal Cancer1 trial

Unresectable Cancer1 trial

COVID-191 trial

Melanoma1 trial

ART1 trial

References

Drug Info

Quick Facts

Related News